K_老虎社区_美港股上老虎

amzl
2021-12-14

FHTX Stock Alert: 7 Things to Know About the Partnership Lifting Foghorn

Shares of Foghorn Therapeutics(NASDAQ:FHTX) are surging higher on Monday by more than 50% after the

FHTX Stock Alert: 7 Things to Know About the Partnership Lifting Foghorn

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":604751286,"tweetId":"604751286","gmtCreate":1639448864950,"gmtModify":1639448935267,"author":{"id":4087650631380140,"authorId":4087650631380140,"authorIdStr":"4087650631380140","name":"amzl","avatar":"https://static.tigerbbs.com/b636c7888902713fcdab7779c592c54c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>K</p></body></html>","htmlText":"<html><head></head><body><p>K</p></body></html>","text":"K","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/604751286","repostId":1157008817,"repostType":4,"repost":{"id":"1157008817","pubTimestamp":1639448366,"share":"https://www.laohu8.com/m/news/1157008817?lang=&edition=full","pubTime":"2021-12-14 10:19","market":"us","language":"en","title":"FHTX Stock Alert: 7 Things to Know About the Partnership Lifting Foghorn","url":"https://stock-news.laohu8.com/highlight/detail?id=1157008817","media":"InvestorPlace","summary":"Shares of Foghorn Therapeutics(NASDAQ:FHTX) are surging higher on Monday by more than 50% after the ","content":"<p>Shares of&nbsp;<b>Foghorn Therapeutics</b>(NASDAQ:<b><u>FHTX</u></b>) are surging higher&nbsp;on Monday by more than 50% after the biopharmaceutical company announced an exciting&nbsp;partnership&nbsp;with&nbsp;<b>Eli Lilly</b>(NYSE:<b><u>LLY</u></b>). The partnership will see Foghorn receive upfront consideration of $300 million in cash. Additionally, there will be an equity investment worth $80 million from Eli Lilly. The equity investment will go into shares of FHTX stock at a price of $20. Indeed, this price represents an upside of 19% from current prices.</p>\n<p>Today, Foghorn CEO Adrian Gottschalk commented on the deal:</p>\n<blockquote>\n “We are excited to be collaborating with the Loxo Oncology at Lilly team to use our platform and utilize Foghorn’s powerful precision biology-first approach to create medicines targeting genetic dependencies within the chromatin regulatory system. This collaboration enables an acceleration and expansion of our pipeline and significantly strengthens our balance sheet as we strive to bring new medicines to patients and their families.”\n</blockquote>\n<p>So, what else is there to know about this compelling new partnership? Let’s dive right in.</p>\n<p>FHTX Stock: What to Know About the New Partnership With Eli Lilly</p>\n<ol>\n <li>Loxo Oncology, which is the research and development arm of Eli Lilly, will collaborate with Foghorn tocreate novel oncology medicinesusing Foghorn’s proprietary Gene Traffic Control platform.</li>\n <li>The collaboration will bring on Eli Lilly as a co-development and co-commercialization partner for Foghorn’s selective Biologic Response Modifiers (BRM) oncology program and also another undisclosed oncology target.</li>\n <li>Additionally, the partnership will include three more discovery programs using Foghorn’s Gene Traffic Control platform.</li>\n <li>For the BRM and undisclosed oncology program, Foghorn will lead discovery and early research activities. Eli Lilly, on the other hand, will lead development and commercialization activities. Both parties will contribute toward operational activities and earn 50/50 in terms of potential U.S. developments. Moreover, Foghorn is eligible to receive royalties on U.S. sales based on potential revenue levels.</li>\n <li>For the discovery programs, Foghorn will lead the discovery and early research activities. Foghorn will have the option to receive a percentage of potential U.S. and foreign sales that can be exercised upon successful completion of the dose-finding toxicity studies. However, Foghorn’s profit is capped at $1.3 billion for potential development and commercialization milestones.</li>\n <li>There will no changes to Eli Lillys’ 2021 non-GAAP earnings per share guidance as a result of this partnership.</li>\n <li>Furthermore, Loxo Oncology CEO Jacob Van Naarden commented: “Foghorn has a differentiated platform and we look forward to the prospect of leveraging it to discover multiple new drugs against similarly challenging targets with strong biologic rationale.”</li>\n</ol>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FHTX Stock Alert: 7 Things to Know About the Partnership Lifting Foghorn</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFHTX Stock Alert: 7 Things to Know About the Partnership Lifting Foghorn\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 10:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/fhtx-stock-alert-7-things-to-know-about-the-partnership-lifting-foghorn-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Foghorn Therapeutics(NASDAQ:FHTX) are surging higher on Monday by more than 50% after the biopharmaceutical company announced an exciting partnership with Eli Lilly(NYSE:LLY). The ...</p>\n\n<a href=\"https://investorplace.com/2021/12/fhtx-stock-alert-7-things-to-know-about-the-partnership-lifting-foghorn-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FHTX":"Foghorn Therapeutics Inc.","LLY":"礼来"},"source_url":"https://investorplace.com/2021/12/fhtx-stock-alert-7-things-to-know-about-the-partnership-lifting-foghorn-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157008817","content_text":"Shares of Foghorn Therapeutics(NASDAQ:FHTX) are surging higher on Monday by more than 50% after the biopharmaceutical company announced an exciting partnership with Eli Lilly(NYSE:LLY). The partnership will see Foghorn receive upfront consideration of $300 million in cash. Additionally, there will be an equity investment worth $80 million from Eli Lilly. The equity investment will go into shares of FHTX stock at a price of $20. Indeed, this price represents an upside of 19% from current prices.\nToday, Foghorn CEO Adrian Gottschalk commented on the deal:\n\n “We are excited to be collaborating with the Loxo Oncology at Lilly team to use our platform and utilize Foghorn’s powerful precision biology-first approach to create medicines targeting genetic dependencies within the chromatin regulatory system. This collaboration enables an acceleration and expansion of our pipeline and significantly strengthens our balance sheet as we strive to bring new medicines to patients and their families.”\n\nSo, what else is there to know about this compelling new partnership? Let’s dive right in.\nFHTX Stock: What to Know About the New Partnership With Eli Lilly\n\nLoxo Oncology, which is the research and development arm of Eli Lilly, will collaborate with Foghorn tocreate novel oncology medicinesusing Foghorn’s proprietary Gene Traffic Control platform.\nThe collaboration will bring on Eli Lilly as a co-development and co-commercialization partner for Foghorn’s selective Biologic Response Modifiers (BRM) oncology program and also another undisclosed oncology target.\nAdditionally, the partnership will include three more discovery programs using Foghorn’s Gene Traffic Control platform.\nFor the BRM and undisclosed oncology program, Foghorn will lead discovery and early research activities. Eli Lilly, on the other hand, will lead development and commercialization activities. Both parties will contribute toward operational activities and earn 50/50 in terms of potential U.S. developments. Moreover, Foghorn is eligible to receive royalties on U.S. sales based on potential revenue levels.\nFor the discovery programs, Foghorn will lead the discovery and early research activities. Foghorn will have the option to receive a percentage of potential U.S. and foreign sales that can be exercised upon successful completion of the dose-finding toxicity studies. However, Foghorn’s profit is capped at $1.3 billion for potential development and commercialization milestones.\nThere will no changes to Eli Lillys’ 2021 non-GAAP earnings per share guidance as a result of this partnership.\nFurthermore, Loxo Oncology CEO Jacob Van Naarden commented: “Foghorn has a differentiated platform and we look forward to the prospect of leveraging it to discover multiple new drugs against similarly challenging targets with strong biologic rationale.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":1000,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}